Enfortumab vedotin + pembrolizumab for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Oct 2025: Trial registered, NCT07221942
  2. 23 Jan 2026: Trial started, NCT07221942

The trials

NCT07221942: Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

State
Under way
Phase
Phase 2
People
97 planned
Started
23 Jan 2026
Primary completion
1 Sep 2028
Arms
Induction EV + Pembrolizumab Followed by Maintenance Pembrolizumab
Results
None posted
  1. 29 Oct 2025: Trial registered
  2. 23 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.